Stockscreener 앱 받기
11.20
107.02%
5.79
전일 마감가:
$5.41
열려 있는:
$11.379
하루 거래량:
33.46M
Relative Volume:
5.78
시가총액:
$940.19M
수익:
-
순이익/손실:
$-313.94M
주가수익비율:
-3.1945
EPS:
-3.506
순현금흐름:
$-284.57M
1주 성능:
+15.46%
1개월 성능:
+1.17%
6개월 성능:
+59.32%
1년 성능:
+59.32%
1일 변동 폭
$9.43
$12.50
1주일 범위
$4.7648
$12.50
52주 변동 폭
$1.50
$12.50
레플리뮨 Stock (REPL) Company Profile
명칭
Replimune Group Inc
전화
(781) 222-9600
주소
500 UNICORN PARK, WOBURN, MA
Compare REPL vs VRTX, REGN, ARGX, RVMD, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
REPL
Replimune Group Inc
|
11.20 | 724.45M | 0 | -313.94M | -284.57M | -3.506 |
VRTX
Vertex Pharmaceuticals Inc
|
477.10 | 121.57B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
762.63 | 69.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
853.82 | 55.61B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
187.53 | 39.98B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
316.01 | 33.81B | 5.76B | 514.49M | 1.10B | 4.4813 |
레플리뮨 Stock (REPL) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-13 | 다운그레이드 | BMO Capital Markets | Market Perform → Underperform |
| 2026-04-13 | 다운그레이드 | H.C. Wainwright | Buy → Sell |
| 2026-04-13 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2026-04-13 | 다운그레이드 | Jefferies | Buy → Hold |
| 2026-04-13 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2026-04-13 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2026-04-10 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2025-11-03 | 업그레이드 | BMO Capital Markets | Underperform → Market Perform |
| 2025-10-27 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2025-10-20 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2025-10-20 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2025-10-20 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2025-10-20 | 업그레이드 | Wedbush | Neutral → Outperform |
| 2025-09-19 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2025-07-30 | 업그레이드 | Cantor Fitzgerald | Neutral → Overweight |
| 2025-07-23 | 다운그레이드 | BMO Capital Markets | Outperform → Underperform |
| 2025-07-23 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2025-07-23 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2025-07-22 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2025-07-22 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2025-07-22 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2025-07-22 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2025-06-20 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-08-28 | 개시 | ROTH MKM | Buy |
| 2023-04-17 | 재개 | Piper Sandler | Overweight |
| 2021-11-19 | 개시 | Piper Sandler | Overweight |
| 2021-10-15 | 재개 | BTIG Research | Buy |
| 2020-11-17 | 개시 | BTIG Research | Buy |
| 2020-11-02 | 개시 | Jefferies | Buy |
| 2020-10-15 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2020-07-01 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2020-05-05 | 개시 | Barclays | Overweight |
| 2019-09-04 | 개시 | ROTH Capital | Buy |
| 2019-07-23 | 개시 | Chardan Capital Markets | Buy |
| 2019-07-12 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2019-07-08 | 개시 | H.C. Wainwright | Buy |
| 2019-04-25 | 개시 | Wedbush | Outperform |
| 2019-01-23 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2018-08-14 | 개시 | JP Morgan | Overweight |
| 2018-08-14 | 개시 | Leerink Partners | Outperform |
모두보기
레플리뮨 주식(REPL)의 최신 뉴스
Wedbush Weighs FDA Advisory Committee Vote on REPL's RP1 Amid Mi - GuruFocus
FDA Staff Raise Concerns On Replimune’s Skin Cancer Drug – REPL Stock Crashes 32% Today Ahead Of Advisory Meeting This Week - Yahoo Finance
FDA staff reiterate concerns about Replimune skin cancer treatment - STAT
Replimune Stock Slides As Losses Deepen And Legal Risks Rise - timothysykes.com
Replimune (REPL) Shares Drop 28% Premarket Amid FDA Concerns Ove - GuruFocus
US FDA staff cast doubt on Replimune cancer drug’s benefit; shares slide - 1470 & 100.3 WMBD
Replimune (REPL) Slumps As Losses Mount And Legal Scrutiny Grows - StocksToTrade
Replimune joins Capricor in post-briefing doc drop (REPL:NASDAQ) - Seeking Alpha
US FDA staff raise efficacy concerns on Replimune's skin cancer drug ahead of meeting - Reuters
Replimune stock tumbles 20% after FDA raises efficacy concerns By Investing.com - Investing.com Nigeria
Replimune Group Inc (REPL) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Replimune Group Market Sentiment - Benzinga España
REPL Stock On Track For Worst Drop In Nearly 7 Months Ahead Of FDA Decision On Skin Cancer Drug - Stocktwits
REPL|Replimune Group Inc|Price:9.700|Chg%:-0.760 - TradingKey
Replimune Group Inc (REPL) Institutional Confidence - TradingKey
Replimune Group Inc (REPL) Valuation: PE, PB & Fair Value Analysis - TradingKey
TradingKey - TradingKey
Replimune Group Inc (REPL) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
REPL Vs IOVA: FDA Decision Day Could Test Biotech Bulls’ Conviction On These Melanoma Plays - Stocktwits
REPL|Replimune Group Inc|Price:8.635|Chg%:-1.065 - TradingKey
Replimune Group Inc (REPL) Cash Flow - TradingKey
Replimune Group Inc (REPL) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Replimune Group (REPL) Q3 2026 Earnings ReportResults, Call & Slides - TipRanks
Lost Money on Replimune Group, Inc. (REPL)? Contact Levi & Korsin - The National Law Review
Replimune Group, Inc. Revenue Breakdown – NASDAQ:REPL - TradingView
Replimune Group Inc (REPL) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Replimune Group, Inc. (REPL) Stock Analysis: Assessing the 1.98% Potential Upside in Biotech - DirectorsTalk Interviews
Replimune stock trades lower after cash burn and clinical updates shape outlook - Ad-hoc-news.de
Replimune's RP1 Drug Probably Works, But It's Not A Buy Yet (NASDAQ:REPL) - Seeking Alpha
REPL Stock Lost 19% Of Its Value Today – Why Did The FDA Refuse Approval For Its Experimental Melanoma Drug? - Stocktwits
Replimune stock gains after updated RP1 data and cash runway outlook - AD HOC NEWS
ETFs Investing in Replimune Group, Inc. Stocks - TradingView
REPL Stock On Track To Hit All-Time Lows – Here’s Why This Analyst Slashed Price Target By 85% - Stocktwits
BMO Capital downgrades Replimune Group (REPL) - MSN
Liquidity Mapping Around (REPL) Price Events - Stock Traders Daily
Johnson Fistel, PLLP Investigates Claims on Behalf of Long-Term Shareholders of Replimune Group, Inc. (REPL) - GlobeNewswire
Form PRE 14A REPLIMUNE GROUP For: 13 July By Investing.com - Investing.com Nigeria
Price to earnings forward of Replimune Group, Inc. – MUN:7R8 - TradingView
Replimune Group (NASDAQ: REPL) seeks approval to double authorized stock - Stock Titan
Replimune Group (REPL) Q4 2026 earnings summary - Quartr
Replimune soars after FDA reconsiders denial of cancer drug - MSN
symbol__ Stock Quote Price and Forecast - CNN
Replimune Group Inc. (REPL) Stock Price | Live Quotes & Charts | NASDAQ - timothysykes.com
9 Health Care Stocks With Whale Alerts In Today’s Session - Benzinga
REPL Stock Rallies In Anticipation Of FDA Decision On Skin Cancer Drug - Stocktwits
레플리뮨 (REPL) 재무 분석
매출
순이익
현금흐름
주당 순 이익
레플리뮨 주식 (REPL) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Xynos Konstantinos | Chief Medical Officer |
May 18 '26 |
Sale |
5.08 |
14,023 |
71,237 |
235,662 |
| Schwendenman Andrew | Chief Accounting Officer |
May 18 '26 |
Sale |
5.08 |
7,894 |
40,102 |
107,057 |
| Sarchi Christopher | Chief Commercial Officer |
May 18 '26 |
Sale |
5.08 |
8,626 |
43,820 |
192,962 |
| Astley-Sparke Philip | Director |
May 18 '26 |
Sale |
5.08 |
17,657 |
89,698 |
1,412,414 |
| Patel Sushil | Chief Executive Officer |
May 18 '26 |
Sale |
5.08 |
37,324 |
189,606 |
747,492 |
| Hill Emily Luisa | Chief Financial Officer |
May 18 '26 |
Sale |
5.08 |
7,812 |
39,685 |
236,556 |
| Sarchi Christopher | Chief Commercial Officer |
Apr 02 '26 |
Sale |
8.01 |
6,500 |
52,065 |
151,588 |
2.44%
0.02%
자본화:
|
볼륨(24시간):